CASI Pharmaceuticals Inc. Stock
The community is currently still undecided about CASI Pharmaceuticals Inc. with 2 Buy predictions and 0 Sell predictions.
Based on the current price of 1.59 € the target price of 10 € shows a potential of 528.93% for CASI Pharmaceuticals Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the CASI Pharmaceuticals Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Customer and product portfolio" there were negative voices in the community.
Pros and Cons of CASI Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CASI Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 0.140% | 44.059% | 24.632% | 107.002% | 49.343% | 55.532% | - |
| Evolus Inc | -1.640% | 14.019% | 1.667% | 60.526% | 34.807% | 65.986% | - |
| Salarius Pharmaceuticals Inc. | -4.230% | 3.398% | -0.930% | -70.417% | -23.243% | -98.252% | -99.993% |
Comments
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CASI provided by MarketBeat
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for CASI provided by MarketBeat